Authored by Tim Olsen, PhD, RoosterBio Inc. Where are we now in our therapeutic response to COVID? As of writing this article, over 1.5 Million Americans have confirmed cases of ... More

Amid the global search for treatments for COVID-19 related lung disorders, MSCs emerged as one of the promising solutions to treat Acute Respiratory Distress Syndrome (ARDS) [1, 2]. (See our ... More

Patient Safety as First Priority in COVID-19 Treatment The medical and scientific communities are ardently working on promising new treatments for COVID-19. With the urgency to treat patients currently affected ... More

Authored by Mayasari Lim, Ph.D. Industry sponsored MSC-based clinical trial activities for COVID-19 As of this writing, more than a dozen companies and groups have announced their interests to develop ... More

Authored by Jonathan Carson, PhD “If you can’t fly then run, if you can’t run then walk, if you can’t walk then crawl, but whatever you do you have to ... More

Authored by Mayasari Lim, PhD, Jonathan Carson, PhD, and Jon A. Rowley, PhD, RoosterBio, Inc. Some research suggests that ARDS might be treatable with the secretome of MSCs. Scientists and ... More

By Jonathan Carson, PhD and Jon A. Rowley, PhD, with acknowledgement to scientists who sounded the alarm like Dr. Liz Specht and to all health workers on the front lines. ... More

Authored by Mayasari Lim | West Coast and APAC lead for RoosterBio   Amidst the scramble and panic-buying that some of us are experiencing, several treatments to combat this novel ... More

Authored by: Jon Carson, Iain Farrance, John Getz, and Jon A. Rowley, RoosterBio, Inc. On 31-December-2019, Chinese officials alerted the World Health Organization of an outbreak of pneumonia cases in ... More

The use of human mesenchymal stem/stromal cells (hMSCs) has evolved since its discovery in the early 1960s. Continuous learning about hMSCs has shifted the paradigm of theses cells. While originally ... More